After admonishing AbbVie for Humira patent and pricing, Sen Ron Wyden takes Richard Gonzalez to task on tax practices
Little has changed since Senator Ron Wyden (D-OR) admonished AbbVie CEO Richard Gonzalez at a Senate Finance Committee hearing for guarding the Humira franchise with a thicket of patents like “Gollum with his ring” — and bagging hefty bonuses along the way. In fact, according to a recent report from the House Oversight Committee, the price of the drug is now 470% higher than when it first entered the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.